Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Shailender Bhatia, MD, on Pembrolizumab in Front-Line Treatment of Merkel Cell Carcinoma

Posted: Friday, December 4, 2020

Shailender Bhatia, MD, of the Fred Hutchinson Cancer Research Center, discusses the KEYNOTE-17 trial and its findings on the efficacy of pembrolizumab in front-line treatment of metastatic Merkel cell carcinoma, safety data on the drug, and the unmet needs of patients with this disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.